title: Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
abstract: Nanocarrier-based drug delivery systems are playing an emerging role in human immunodeficiency virus (HIV) chemoprophylaxis and treatment due to their ability to alter the pharmacokinetics and improve the therapeutic index of various antiretroviral (ARV) drug compounds used alone and in combination. Although several nanocarriers have been described for combination delivery of ARV drugs, measurement of drug-drug activities facilitated by the use of these nanotechnology platforms has not been fully investigated for topical prevention. Here, we show that physicochemically diverse ARV drugs can be encapsulated within polymeric nanoparticles to deliver multidrug combinations that provide potent HIV chemoprophylaxis in relevant models of cell-free, cell-cell, and mucosal tissue infection. In contrast to existing approaches that coformulate ARV drug combinations together in a single nanocarrier, we prepared single-drug-loaded nanoparticles that were subsequently combined upon administration. ARV drug-nanoparticles were prepared using emulsion-solvent evaporation techniques to incorporate maraviroc (MVC), etravirine (ETR), and raltegravir (RAL) into poly(lactic-co-glycolic acid) (PLGA) nanoparticles. We compared the antiviral potency of the free and formulated drug combinations for all pairwise and triple drug combinations against both cell-free and cell-associated HIV-1 infection in vitro. The efficacy of ARV-drug nanoparticle combinations was also assessed in a macaque cervicovaginal explant model using a chimeric simian-human immunodeficiency virus (SHIV) containing the reverse transcriptase (RT) of HIV-1. We observed that our ARV-NPs maintained potent HIV inhibition and were more effective when used in combinations. In particular, ARV-NP combinations involving ETR-NP exhibited significantly higher antiviral potency and dose-reduction against both cell-free and cell-associated HIV-1 BaL infection in vitro. Furthermore, ARV-NP combinations that showed large dose-reduction were identified to be synergistic, whereas the equivalent free-drug combinations were observed to be strictly additive. Higher intracellular drug concentration was measured for cells dosed with the triple ARV-NP combination compared to the equivalent unformulated drugs. Finally, as a first step toward evaluating challenge studies in animal models, we also show that our ARV-NP combinations inhibit RT-SHIV virus propagation in macaque cervicovaginal tissue and block virus transmission by migratory cells emigrating from the tissue. Our results demonstrate that ARV-NP combinations control HIV-1 transmission more efficiently than free-drug combinations. These studies provide a rationale to better understand the role of nanocarrier systems in facilitating multidrug effects in relevant cells and tissues associated with HIV infection.
authors.affiliation: Department of Bioengineering, University of Washington , Seattle, Washington 98195, United States.
authors.forename: Yonghou
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Bioengineering, University of Washington , Seattle, Washington 98195, United States.
authors.forename: Shijie
authors.initials: S
authors.lastname: Cao
authors.affiliation: Department of Chemistry, Seattle University , Seattle, Washington 98122, United States.
authors.forename: Danielle K
authors.initials: DK
authors.lastname: Bright
authors.affiliation: Department of Chemistry, Seattle University , Seattle, Washington 98122, United States.
authors.forename: Alaina M
authors.initials: AM
authors.lastname: Bever
authors.affiliation: Department of Bioengineering, University of Washington , Seattle, Washington 98195, United States.
authors.forename: Anna K
authors.initials: AK
authors.lastname: Blakney
authors.affiliation: Department of Chemistry, Seattle University , Seattle, Washington 98122, United States.
authors.forename: Ian T
authors.initials: IT
authors.lastname: Suydam
authors.affiliation: Department of Bioengineering, University of Washington , Seattle, Washington 98195, United States.
authors.forename: Kim A
authors.initials: KA
authors.lastname: Woodrow
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D004337:Drug Carriers / Q000737:chemistry; D004338:Drug Combinations; D016503:Drug Delivery Systems / Q000379:methods; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000187:drug effects*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D008251:Macaca; D053758:Nanoparticles / Q000008:administration & dosage*; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D019380:Anti-HIV Agents; D004337:Drug Carriers; D004338:Drug Combinations; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D054303:HIV Reverse Transcriptase
keywords: ARV combination; HIV; antiretroviral therapy and prophylaxis; drug delivery; nanoparticles